Navigation Links
New class of compounds stops disease-fueling inflammation in lab tests
Date:2/23/2012

CINCINNATI Scientists have developed a unique compound that in laboratory tests blocks inflammation-causing molecules in blood cells known to fuel ailments like cancer and cardiovascular disease without causing harmful toxicity.

Past attempts to identify new compounds that tamp down so-called reactive oxygen species (ROS) molecules in cells have been complicated by toxicity issues and a lack of specificity in targeting molecular processes. Researchers from Cincinnati Children's Hospital Medical Center report in the Feb. 24 Chemistry and Biology (a Cell Press publication) they have overcome this problem.

They did so by using computer-assisted drug design verified by laboratory tests on human and mouse inflammatory cells to precisely target a single component of an enzyme network called NOX2. The enzyme network drives ROS production in immune system white blood cells known as neutrophils. The eventual goal, researchers say, is establishing new small-molecule inhibiting drugs that can stop excessive inflammation and treat a number of inflammation-mediated diseases that need improved therapies.

"Drugs that potently and specifically target ROS production by NOX2 enzyme are an unmet clinical need that will have far-reaching implications for treatment of disease," said Yi Zheng, PhD, a lead investigator on the study and director of Experimental Hematology/Cancer Biology at Cincinnati Children's. "The lead candidate we developed, Phox-I, shows promising inflammation inhibiting activity in cells and mouse models."

The production of ROS in cells is a normal part of the body's immune system, as oxidative enzymes are generated by white blood cells to attack illness-causing microorganisms. In a number of pathologic conditions, however, various environmental stressors (like acute ischemia, chronic infections, etc.) can help trigger an overabundance of biochemical signaling. The signaling occurs through a regulatory pathway involving Rac GTPases, a family of intracellular signal transducers that amplify ROS production by the NOX2 enzyme network.

Normally, Rac GTPases maintain cell growth and survival programs in the body, including the NOX enzyme network and its activation of ROS production in cells. When signaling miscues occur they cause an unusually high burst of ROS production and release harmful superoxide chemicals. This up-regulation creates excessive inflammation that damages tissues and drives the onset of diseases like Chronic Obstructive Pulmonary Disease, ischemia-induced lung and brain damage and hypertension, among others.

Previous attempts to create compounds that target and stop harmful ROS production, including an earlier compound developed by Dr. Zheng's laboratory, have been able to reduce inflammation in cells. Unfortunately, the compounds were not specific or efficient enough in targeting the Rac GTPase regulatory pathway. This meant the compounds inhibited several different cellular processes including some that are necessary and beneficial leading to toxicity.

Zheng and his colleagues achieved greater specificity and efficiency through their design of small molecular inhibitors they named Phox-I1 and Phox-I2. The inhibitors precisely target and block the binding of a signal sensor for the NOX2 enzyme called p67-phox to Rac GTPase. P67-phox has to bind with Rac GTPase to activate the oxidase enzyme complex of NOX2 (known as NADPH) that produces superoxide and causes inflammation.

In laboratory tests involving normal human blood cells, leukemic cells and mouse blood cells, Phox-l1blocked p67-phox binding with Rac. It did so in a dose-dependent manner with enough precision to shut down ROS production without causing unwanted toxicity in the cells, the researchers report. In unpublished test results on mouse models of lung inflammation, Zheng said the investigators found that the Phox-I lead compounds are effective in blocking neutrophil mediated inflammation and damage.

The results are part of a patient application filed by Cincinnati Children's with the United States Patent Office for Phox-I inhibitors. The medical center's Center for Technology Commercialization is exploring opportunities to rapidly advance continuing research and development of the compounds that could possibly accelerate their transition to future clinical testing.

Zheng said that although the study data describe an innovative approach that shows promise, a significant amount of additional research is needed before the Phox-I can be tested in humans. The research team continues to experiment with structural alterations to Phox-I to make the compounds more potent in inhibiting excessive ROS and superoxide production without being toxic to normal cells. Researchers are also expanding their tests in mouse models to see how effective the compounds are in safely shutting down the onset of simulated human diseases caused by inflammation.


'/>"/>
Contact: Nick Miller
nicholas.miller@cchmc.org
513-803-6035
Cincinnati Children's Hospital Medical Center
Source:Eurekalert

Related medicine news :

1. New fibrosis classification improves accuracy of diagnosis in hepatitis C
2. JSCM publishes revised International Standards for Neurological Classification of Spinal Cord Injury
3. New class of drugs for the reversible inhibition of proteasomes
4. Dual-acting class of antimalarial compounds discovered by Novartis with potential to prevent and treat malaria
5. Scripps Research scientists identify new class of antimalarial compounds
6. Focus on testing hurts students in high school health classes
7. Cooking Class Benefits Kids in Many Ways
8. Classic Restless Legs Syndrome Not Linked to Parkinsons
9. Report calls for creation of a biomedical research and patient data network for more accurate classification of diseases, move toward precision medicine
10. Yoga, Stretching Classes Outdo Self-Care for Back Pain: Study
11. Goldie Hawn to give public lecture on The Brain and the Optimistic Classroom at Aspen Brain Forum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2017)... ... 2017 , ... "TransFreeze Volume 3 is a self animating masking transition which allows users to ... X," said Christina Austin - CEO of Pixel Film Studios. , TransFreeze Volume 3 ... one clip to the next. , To use “Cut-Out First” presets, choose a ...
(Date:1/13/2017)... (PRWEB) , ... January 13, 2017 , ... The 18th ... Avenida America hotel on March 3-4, 2017. This Congress is expertly designed to ... the management of patients with lung cancer. , Chaired by Dr. Giorgio V. Scagliotti, ...
(Date:1/13/2017)... ... 2017 , ... KOAMTAC ®, Inc., a leading manufacturer of Bluetooth barcode ... scanner and data collector at the National Retail Federation’s Big Show (NRF17) held January ... to the market’s need for more compact and rugged devices for collecting barcode data ...
(Date:1/13/2017)... PA (PRWEB) , ... January 13, 2017 , ... An inventor from Pahrump, Nev., used ... others. "My urologist had me wear a Foley catheter and urine bag for a half ... and uncomfortable, so I decided that there should be a better way to do this." ...
(Date:1/13/2017)... MN (PRWEB) , ... January 13, 2017 , ... People ... to endure jolts of pain whenever they brush their teeth. Sadly, most dental hygiene ... who have sensitive gums and teeth. For these people, continuing their daily oral care ...
Breaking Medicine News(10 mins):
(Date:1/16/2017)... LONDON , Jan. 16, 2017 ... delivering devices used for administering medications in a ... mainly used for therapeutic purposes in critical care, ... are required to make patient,s feel comfortable and ... medical errors which would lead to serious life ...
(Date:1/16/2017)...   The Harrington Discovery Institute at ... , has announced the 2017 recipients of Harrington ... physician-scientists whose research shows promise to advance the ... Institute – part of The Harrington Project for ... academic medicine: to advance early breakthroughs into the ...
(Date:1/16/2017)... According to the new market research report "Display Controller Market by ... LCD Controller), Application (Industrial Control, Medical Equipment, Automotive, Mobile Communication), and Geography ... to grow from USD 17.26 Billion in 2015 to reach USD 32.24 ... Continue Reading ... ...
Breaking Medicine Technology: